Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis

Highlights • We analyzed 29 patients with relapsed/refractory DLBCL treated with combination BR. • The median PFS was 8 months for all patients (95% CI 5.5–26.6). • The median DOR was 24.7 months (95% CI 3.2–24.7). • Five patients experienced long-lasting responses (+18, +26, +28, +32, +37 months)....

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2014-12, Vol.38 (12), p.1446-1450
Main Authors: Merchionne, Francesca, Quintana, Giovanni, Gaudio, Francesco, Minoia, Carla, Specchia, Giorgina, Guarini, Attilio, Quarta, Giovanni, Pavone, Vincenzo, Melpignano, Angela
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Bendamustine
Bendamustine Hydrochloride
Disease-Free Survival
DLBCL
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Nitrogen Mustard Compounds - administration & dosage
Recurrence
Retrospective Studies
Rituximab
Salvage therapy
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We analyzed 29 patients with relapsed/refractory DLBCL treated with combination BR. • The median PFS was 8 months for all patients (95% CI 5.5–26.6). • The median DOR was 24.7 months (95% CI 3.2–24.7). • Five patients experienced long-lasting responses (+18, +26, +28, +32, +37 months). • R-IPI before therapy, LDH, and number of prior treatments seem to affect response.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2014.10.001